Grand Pharma (00512) saw its shares rise more than 4% during trading. At the time of writing, the stock was up 2.87%, trading at HK$6.80 with a turnover of HK$9.3711 million.
On April 13, Grand Pharma announced that its yttrium-90 microsphere injection has successfully met the preset clinical endpoints in a U.S. clinical study (DOORwaY90 trial) for treating unresectable hepatocellular carcinoma (HCC), achieving outstanding clinical results. The impressive data not only signifies that the SIR-Spheres individualized dosimetry treatment model has surpassed traditional treatment options but also expands the application scope of liver-directed therapy for patients with unresectable HCC. This further highlights the product's strong efficacy and market potential, which is expected to drive sustained high-volume sales of Grand Pharma's yttrium-90 microsphere injection in global markets.
It is worth noting that, based on breakthrough interim data from the DOORwaY90 trial, the U.S. FDA has already granted formal approval for the use of yttrium-90 microsphere injection in treating unresectable hepatocellular carcinoma. This makes it the world's first and only selective internal radiotherapy product approved by the FDA for dual indications in unresectable HCC and colorectal cancer liver metastases. The relevant clinical data will also provide strong support for expanding indications in China.
Comments